Viking Therapeutics

Viking Therapeutics has appointed Dorothy Gemmell to its board of directors with immediate effect. Gemmell brings more than 25 years of experience in healthcare, digital health and commercialization, having held leadership roles at GoodRx, Capsule and Havas Life. The company says the appointment will bolster its commercialization capabilities as it advances the launch of the GLP‑1/GIP agonist VK2735; other programs include VK3019, VK2809 and VK0214. » Altro su de.investing.com

Viking Therapeutics is developing VK2735, a dual GLP‑1/GIP candidate in both injectable and oral formulations that showed mid‑teens weight loss at 13 weeks in phase 2 trials. The company is running a phase 1 maintenance study with various dosing regimens, with subcutaneous maintenance data expected in Q3 2026 and phase 3 readouts for injectable and oral forms slated from mid‑late 2027 through 2029. Risks include strong competition from established GLP‑1 players and tolerability concerns in the phase 2 oral trial, but successful maintenance or phase 3 data could make Viking an acquisition target. » Altro su finance.yahoo.com

Viking Therapeutics, a biotech developing drugs for anemia and NASH, has risen about 49% over the past year but is down 2.4% year-to-date. Shares fell 42% on August 19 after VK-2735 mid-stage results showed 12% average weight loss, below some investor expectations, and have since recovered about 41%. Jim Cramer had advised selling the stock in January 2025; the article compares Viking’s prospects with other investment ideas but provides no new company guidance. » Altro su finance.yahoo.com